Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study

SY Rha, LS Wyrwicz, P Yañez, Y Bai, M-H Ryu, J Lee, F Rivera, G Vasconcelos Alves, M Garrido, K-K Shiu, M González Fernández, J Li, MA Lowery, T Çil, F Melo Cruz, D-Y Oh, A Wang, P Leconte, S Qin · 2026

Read Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study by SY Rha, LS Wyrwicz, P Yañez, Y Bai, M-H Ryu, J Lee, F Rivera, G Vasconcelos Alves, M Garrido, K-K Shiu, M González Fernández, J Li, MA Lowery, T Çil, F Melo Cruz, D-Y Oh, A Wang, P Leconte, S Qin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13595130.txt.

Description

Rha and co-authors report four and a half year results from a large stomach cancer drug trial in a 2026 paper. Near sixteen hundred patients with advanced HER2 negative tumors joined the study. Half got an immune drug plus chemotherapy, and half got placebo plus chemotherapy. Survival led the outcome list, with response and safety beside it.

Median survival ran about thirteen months on the drug arm versus eleven and a half on placebo. Gains grew larger in tumors with higher immune marker scores. Severe side effects hit about fifty-eight percent on the drug arm. Deaths from treatment stayed near one to two percent in both arms. Long follow up backs the combo as a first line standard.

Catalog record

CREATORSY Rha, LS Wyrwicz, P Yañez, Y Bai, M-H Ryu, J Lee, F Rivera, G Vasconcelos Alves, M Garrido, K-K Shiu, M González Fernández, J Li, MA Lowery, T Çil, F Melo Cruz, D-Y Oh, A Wang, P Leconte, S Qin
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13595130

Browse the full library · About the Tower of Babel